EMA Authorised: Dacogen (decitabine) — Janssen-Cilag International N.V.

View source ↗

Summary

The EMA authorised Dacogen (decitabine) for use in myeloid leukemias, including myelodysplastic syndromes and acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Dacogen (decitabine)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid. MAH: Janssen-Cilag International N.V.. Decision date: 01/10/2024